Dr. Klebanoff on Biosimilars Reducing Financial Toxicity in Breast Cancer

Video

In Partnership With:

Christopher A. Klebanoff, MD, discusses using biosimilars to reduce financial toxicity in breast cancer.

Christopher A. Klebanoff, MD, medical oncologist, head, Breast Immunotherapy Section, Memorial Sloan Kettering Cancer Center, discusses using biosimilars to reduce financial toxicity in breast cancer.

Biosimilars will greatly reduce the financial toxicity of many therapeutics available to patients with breast cancer, most notably patients with HER2-positive disease, explains Klebanoff. In addition to the cancer treatments, there are other biologics, specifically granulocyte-colony stimulating factor, that are commonly used in the adjuvant setting as a neutrophil immune booster that can also cause financial toxicity, says Klebanoff.

With biosimilars, the registration data demonstrate equivalence similar to conventional generics in terms of efficacy and reduced financial cost, making them a positive option for patients and providers, concludes Klebenoff.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD